A Phase 3 interventional study of pregabalin and levetiracetam in Partial Seizures, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 73 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing pregabalin in Seizures — none open to participants now, none under way, none of them phase 3. Pregabalin · Seizures.
Among the 10 studies testing pregabalin in Seizures, this one is the 4th largest by enrollment, is one of 3 that started in 2007, is one of 7 in phase 3, and was the 7th registered.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
Browse Seizures studies →None of the 10 studies testing pregabalin in Seizures is open now. The open studies under Seizures, anywhere →
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2007.
This study's enrollment of 509 is above the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 276 across the 10 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 2 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
12 studies in Seizures by Viatris Inc.: none open now, none under way, none of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 12 studies in Seizures by Viatris Inc., this one is the 4th largest by enrollment, is one of 3 that started in 2007, is one of 9 in phase 3, and was the 7th registered.
Viatris Inc.’s Seizures studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing pregabalin in Seizures, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 12 in Seizures:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare pregabalin and levetiracetam in patients with partial seizures. It will also evaluate the safety and tolerability of pregabalin and levetiracetam in these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: pregabalin
Drug: levetiracetam
300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
Proportion of Participants With Response to Treatment
Participants who had at least 50% reduction in 28-day seizure rate from baseline to the end of the maintenance phase were considered as responders. The 28-day seizure rate was calculated as number of partial seizures in the period divided by difference of number of days in the period and number of missing diary day entries in the period, multiplied by 28.
Time frame: Baseline up to Week 16
Percent Change From Baseline in 28 Day Seizure Frequency at Week 16
The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline.
Time frame: Baseline, Week 16
Change From Baseline in the Proportion of 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Rate to 28-day All Partial Seizure Rate at Week 16
Change was calculated as (proportion of SGTC seizure rate divided by all partial seizure rates during double blind phase) minus (proportion of SGTC seizure rate divided by all partial seizure rates at baseline). Negative values indicated reductions in seizures.
Time frame: Baseline, Week 16
Percentage of Participants Without Seizures
Seizure free for 28 days was defined as participants who have not experienced any seizure (simple partial, complex partial and SGTC) for at least 28 consecutive days from their last seizure until the end of the maintenance phase. Same participant could be seizure free for a specific type of seizure but not necessarily for the other types of seizure.
Time frame: Baseline up to Week 16
Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total and Core Score at Week 7, 10, 13, 16 and Follow-up
BPRS-A:18-item clinician rated scale assesses somatic concern,anxiety, emotional withdrawal,conceptual disorganization,hallucinatory behavior(HB), guilt feelings,suspiciousness,disorientation,tension,mannerisms and posturing,grandiosity,depressive mood,hostility,motor retardation,uncooperativeness,unusual thought content,blunted affect,excitement. Items rated on 7-point scale 1 (not reported) to 7 (very severe). Total score=sum of items(range 18-126), core score=sum of conceptual disorganization, suspiciousness, HB, unusual thought content(range 4-28). Higher total/core score=more impairment.
Time frame: Baseline, Week 7, 10, 13, 16 and Follow-up (Day 7 of taper phase)
Hospital Anxiety and Depression Scale (HADS) Score
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Time frame: Baseline, Week 16
Medical Outcomes Study Sleep Scale (MOS-SS) Score
Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales:sleep disturbance,snoring,awakened short of breath,sleep adequacy,somnolence (range:0-100);sleep quantity (range:0-24),optimal sleep(yes/no), and 9 item index measures of sleep disturbance provide composite scores:sleep problem summary,overall sleep problem. Except adequacy,optimal sleep and quantity, higher scores=more impairment. Scores transformed (actual raw score\[RS\] minus lowest possible score divided by possible RS range\*100);total score range:0-100;higher score=more intensity of attribute.
Time frame: Baseline, Week 16
Percentage of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) Score
MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Percentage of participants with optimal sleep are reported.
Time frame: Baseline, Week 16
| Milestone | Pregabalin | Levetiracetam |
|---|---|---|
| Started | 254 | 255 |
| Completed titration phase | 226 | 236 |
| Completed maintenance phase | 208 | 210 |
| Entered opt blinded continuation phase | 185 | 195 |
| Completed | 80 | 82 |
| Not completed | 174 | 173 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Adverse event | 31 | 22 |
| Withdrew: Lack of efficacy | 20 | 21 |
| Withdrew: Lost to follow-up | 12 | 8 |
| Withdrew: Withdrawal by subject | 51 | 47 |
| Withdrew: Protocol violation | 15 | 19 |
| Withdrew: Does not meet entrance criteria | 0 | 2 |
| Withdrew: Other | 44 | 52 |
Participants who had at least 50% reduction in 28-day seizure rate from baseline to the end of the maintenance phase were considered as responders. The 28-day seizure rate was calculated as number of partial seizures in the period divided by difference of number of days in the period and number of missing diary day entries in the period, multiplied by 28.
| proportion of participants | Pregabalin | Levetiracetam |
|---|---|---|
| Proportion of Participants With Response to Treatment | 0.59 | 0.59 |
The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline.
| percent change | Pregabalin | Levetiracetam |
|---|---|---|
| Percent Change From Baseline in 28 Day Seizure Frequency at Week 16 | -53.93 (-100.0 to 533.1) | -57.28 (-100.0 to 276.9) |
Change was calculated as (proportion of SGTC seizure rate divided by all partial seizure rates during double blind phase) minus (proportion of SGTC seizure rate divided by all partial seizure rates at baseline). Negative values indicated reductions in seizures.
| percentage of all partial seizure/28days | Pregabalin | Levetiracetam |
|---|---|---|
| Baseline (n=107, 111) | 39.41 ± 38.141 | 38.94 ± 35.870 |
| Change at Week 16 (n=102, 101) | 3.93 ± 30.158 | 6.33 ± 32.071 |
Seizure free for 28 days was defined as participants who have not experienced any seizure (simple partial, complex partial and SGTC) for at least 28 consecutive days from their last seizure until the end of the maintenance phase. Same participant could be seizure free for a specific type of seizure but not necessarily for the other types of seizure.
| percentage of participants | Pregabalin | Levetiracetam |
|---|---|---|
| All Partial Seizure | 19.9 (14.4 to 25.4) | 27.6 (21.6 to 33.7) |
| Simple Partial Seizure | 65.7 (59.1 to 72.2) | 66.2 (59.8 to 72.6) |
| Complex Partial Seizure | 49.3 (42.3 to 56.2) | 59.0 (52.4 to 65.7) |
| SGTC Seizure | 80.6 (75.1 to 86.1) | 79.0 (73.5 to 84.6) |
BPRS-A:18-item clinician rated scale assesses somatic concern,anxiety, emotional withdrawal,conceptual disorganization,hallucinatory behavior(HB), guilt feelings,suspiciousness,disorientation,tension,mannerisms and posturing,grandiosity,depressive mood,hostility,motor retardation,uncooperativeness,unusual thought content,blunted affect,excitement. Items rated on 7-point scale 1 (not reported) to 7 (very severe). Total score=sum of items(range 18-126), core score=sum of conceptual disorganization, suspiciousness, HB, unusual thought content(range 4-28). Higher total/core score=more impairment.
| units on a scale | Pregabalin | Levetiracetam |
|---|---|---|
| Baseline: Total BPRS-A Score (n=253, 254) | 27.26 ± 0.55 | 26.09 ± 0.56 |
| Baseline: Core BPRS-A Score (n=253, 254) | 5.18 ± 0.13 | 5.01 ± 0.13 |
| Change at Week 7: Total BPRS-A Score (n=217, 225) | -2.16 ± 0.36 | -1.70 ± 0.36 |
| Change at Week 7: Core BPRS-A Score (n=216, 225) | -0.34 ± 0.08 | -0.22 ± 0.08 |
| Change at Week 10: Total BPRS-A Score (n=217, 219) | -2.64 ± 0.37 | -2.42 ± 0.38 |
| Change at Week 10: Core BPRS-A Score (n=217, 219) | -0.40 ± 0.08 | -0.34 ± 0.08 |
| Change at Week 13: Total BPRS-A Score (n=209, 214) | -2.99 ± 0.39 | -2.68 ± 0.39 |
| Change at Week 13: Core BPRS-A Score (n=209, 214) | -0.51 ± 0.07 | -0.38 ± 0.07 |
| Change at Week 16: Total BPRS-A Score (n=235, 241) | -2.70 ± 0.40 | -1.92 ± 0.40 |
| Change at Week 16: Core BPRS-A Score (n=235, 241) | -0.40 ± 0.08 | -0.26 ± 0.08 |
| Change at Follow-up: Total BPRS-A Score(n=178,189) | -2.77 ± 0.44 | -1.42 ± 0.43 |
| Change at Follow-up: Core BPRS-A Score(n=178,189) | -0.37 ± 0.10 | -0.11 ± 0.10 |
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
| units on a scale | Pregabalin | Levetiracetam |
|---|---|---|
| Baseline: HADS-A (n=253, 253) | 7.25 ± 0.26 | 7.34 ± 0.27 |
| Baseline: HADS-D (n=253, 253) | 6.22 ± 0.25 | 6.00 ± 0.25 |
| Week 16: HADS-A (n=228, 241) | 6.32 ± 0.22 | 6.06 ± 0.22 |
| Week 16: HADS-D (n=228, 241) | 5.41 ± 0.22 | 5.42 ± 0.22 |
Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales:sleep disturbance,snoring,awakened short of breath,sleep adequacy,somnolence (range:0-100);sleep quantity (range:0-24),optimal sleep(yes/no), and 9 item index measures of sleep disturbance provide composite scores:sleep problem summary,overall sleep problem. Except adequacy,optimal sleep and quantity, higher scores=more impairment. Scores transformed (actual raw score\[RS\] minus lowest possible score divided by possible RS range\*100);total score range:0-100;higher score=more intensity of attribute.
| units on a scale | Pregabalin | Levetiracetam |
|---|---|---|
| Baseline: Sleep Disturbance (n=253, 253) | 27.06 ± 1.45 | 28.10 ± 1.48 |
| Baseline: Snoring (n=253, 254) | 30.72 ± 2.25 | 32.42 ± 2.29 |
| Baseline: Awaken Short of Breath (n=253, 254) | 15.72 ± 1.54 | 17.26 ± 1.57 |
| Baseline: Quantity of Sleep (n=252, 252) | 7.77 ± 0.10 | 7.82 ± 0.10 |
| Baseline: Adequacy of Sleep (n=253, 254) | 62.96 ± 1.79 | 64.40 ± 1.83 |
| Baseline: Somnolence (n=253, 254) | 34.85 ± 1.43 | 33.77 ± 1.45 |
| Baseline: Sleep Problem Index (9) (n=253, 253) | 29.62 ± 1.16 | 29.49 ± 1.18 |
| Week 16: Sleep Disturbance (n=230, 241) | 21.97 ± 1.16 | 23.61 ± 1.17 |
| Week 16: Snoring (n=230, 240) | 33.77 ± 1.72 | 23.75 ± 1.73 |
| Week 16: Awaken Short of Breath (n=230, 241) | 15.15 ± 1.48 | 14.27 ± 1.48 |
| Week 16: Quantity of Sleep (n=230, 241) | 7.89 ± 0.09 | 7.75 ± 0.09 |
| Week 16: Adequacy of Sleep (n=230, 241) | 63.46 ± 1.72 | 66.46 ± 1.73 |
| Week 16: Somnolence (n=230, 241) | 31.56 ± 1.33 | 32.29 ± 1.34 |
| Week 16: Sleep Problem Index (9) (n=230, 241) | 26.64 ± 0.95 | 26.00 ± 0.96 |
MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Percentage of participants with optimal sleep are reported.
| percentage of participants | Pregabalin | Levetiracetam |
|---|---|---|
| Baseline (n=252, 252) | 56.0 | 55.6 |
| Week 16 (n=230, 241) | 58.3 | 50.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 24/254 (9.4%) | 148/254 (58.3%) |
| Levetiracetam | — | 24/255 (9.4%) | 127/255 (49.8%) |
| Event | Pregabalin | Levetiracetam |
|---|---|---|
| ConvulsionNervous system disorders | 5/254 | 1/255 |
| Weight increasedInvestigations | 2/254 | 0/255 |
| EpilepsyNervous system disorders | 1/254 | 2/255 |
| Status epilepticusNervous system disorders | 1/254 | 2/255 |
| AggressionPsychiatric disorders | 0/254 | 2/255 |
| Suicide attemptPsychiatric disorders | 0/254 | 2/255 |
| NeutropeniaBlood and lymphatic system disorders | 1/254 | 0/255 |
| GastroduodenitisGastrointestinal disorders | 1/254 | 0/255 |
| AstheniaGeneral disorders | 1/254 | 0/255 |
| DrowningGeneral disorders | 1/254 | 0/255 |
| Event | Pregabalin | Levetiracetam |
|---|---|---|
| SomnolenceNervous system disorders | 83/254 | 76/255 |
| DizzinessNervous system disorders | 59/254 | 42/255 |
| HeadacheNervous system disorders | 37/254 | 30/255 |
| Weight increasedInvestigations | 26/254 | 8/255 |
| NasopharyngitisInfections and infestations | 24/254 | 19/255 |
| NauseaGastrointestinal disorders | 5/254 | 15/255 |
| InsomniaPsychiatric disorders | 5/254 | 15/255 |
| Age, Continuous(years) | Pregabalin | Levetiracetam | Total |
|---|---|---|---|
| Mean | 32.7 ± 11.2 | 36.3 ± 12.2 | 34.5 ± 11.8 |
| Sex: Female, Male(Participants) | Pregabalin | Levetiracetam | Total |
|---|---|---|---|
| Female | 134 | 130 | 264 |
| Male | 120 | 125 | 245 |
The record gives a start of Oct 2007, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pregabalin · Levetiracetam
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →